Michael Martin - Aurinia Pharmaceuticals Chief Officer
| AUPH Stock | USD 8.86 0.01 0.11% |
Executive
Mr. Michael R. Martin is Chief Operating Officer of Aurinia Pharmaceuticals Inc. He was formerly CEO, director and cofounder of the privately held Aurinia Pharma Corporationration which was acquired in 2013 by the Company. In his current role with Aurinia, Mr. Martin is responsible for managing company functions such as corporate and business development, alliance management, investor relations, intellectual property and precommercial market planning. Mr. Martin is a biotechpharmaceutical executive with over 19 years industry experience. Mr. Martin joined Aurinia from Vifor Pharma where he held the position of Director, Global Business Development Licensing. Prior to Vifor, Mr. Martin was a key member of the business development team that saw Aspreva sold to Galenica for 915M. Upon joining Aspreva in 2004, Mr. Martin initiated the strategic launch planning process for CellCept in lesscommon autoimmune diseases. These included such indications as pemphigus vulgaris, myasthenia gravis, and lupus nephritis. Prior thereto, Mr. Martin held a variety of progressively senior commercial positions at ScheringPlough. Mr. Martin spent time in Europe where he was responsible for the rheumatology business unit for Remicade in France. In addition while at ScheringPlough, Mr. Martin was the brand manager responsible for the Canadian launch of Remicade . since 2014.
| Age | 52 |
| Tenure | 10 years |
| Address | 118 Avenue , 14315, Edmonton, AB, Canada, T5L 4S6 |
| Phone | 250 744 2487 |
| Web | https://www.auriniapharma.com |
Michael Martin Latest Insider Activity
Tracking and analyzing the buying and selling activities of Michael Martin against Aurinia Pharmaceuticals stock is an integral part of due diligence when investing in Aurinia Pharmaceuticals. Michael Martin insider activity provides valuable insight into whether Aurinia Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Aurinia Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Aurinia Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Michael Martin over a year ago Acquisition by Michael Martin of 107202 shares of Aurinia Pharmaceuticals subject to Rule 16b-3 |
Aurinia Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.0216) % which means that it has lost $0.0216 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0578) %, meaning that it created substantial loss on money invested by shareholders. Aurinia Pharmaceuticals' management efficiency ratios could be used to measure how well Aurinia Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.15. The current Return On Capital Employed is estimated to decrease to -0.2. As of now, Aurinia Pharmaceuticals' Total Current Assets are increasing as compared to previous years. The Aurinia Pharmaceuticals' current Intangible Assets is estimated to increase to about 7 M, while Return On Tangible Assets are projected to decrease to (0.15).Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Geoffrey Barker | Viking Therapeutics | N/A | |
| Linda Carter | PTC Therapeutics | N/A | |
| Dana Aftab | Exelixis | 60 | |
| Ari Maizel | Axsome Therapeutics | N/A | |
| Clint Wallace | Madrigal Pharmaceuticals | N/A | |
| Patrick Lamy | Akero Therapeutics | 51 | |
| Edward Chiang | Madrigal Pharmaceuticals | N/A | |
| Diana Chung | Terns Pharmaceuticals | N/A | |
| JD Esq | Terns Pharmaceuticals | 55 | |
| Lisa MD | Seres Therapeutics | 65 | |
| Pierre MS | PTC Therapeutics | 38 | |
| Emil MD | Terns Pharmaceuticals | 44 | |
| CPA CPA | Viking Therapeutics | 53 | |
| Hunter Esq | Axsome Therapeutics | 44 | |
| Hege SollieZetlmayer | PTC Therapeutics | N/A | |
| Scott Harris | Terns Pharmaceuticals | N/A | |
| Alison Nasisi | Sarepta Therapeutics | N/A | |
| Adam Waldman | TG Therapeutics | N/A | |
| Shannon Kelley | Madrigal Pharmaceuticals | N/A | |
| Frank Yocca | BioXcel Therapeutics | 68 | |
| Jeffrey JD | Exelixis | 55 | |
Management Performance
| Return On Equity | -0.0578 | ||||
| Return On Asset | -0.0216 |
Aurinia Pharmaceuticals Leadership Team
Elected by the shareholders, the Aurinia Pharmaceuticals' board of directors comprises two types of representatives: Aurinia Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aurinia. The board's role is to monitor Aurinia Pharmaceuticals' management team and ensure that shareholders' interests are well served. Aurinia Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aurinia Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Chris Hays, VP Marketing | ||
| Premchandran Ramiya, Senior Chain | ||
| Peter MBA, CEO President | ||
| Joseph CPA, Chief Officer | ||
| Ann Daus, Senior Quality | ||
| Andrea Christopher, Head Relations | ||
| Michael Martin, Chief Officer | ||
| Fran Lynch, Vice Sales | ||
| Matthew MBA, Executive Strategy | ||
| Sue Evans, Senior Affairs | ||
| Scott Habig, Chief Officer | ||
| Gregory MD, Chief Officer | ||
| MD DSc, Executive Development | ||
| Stephen Robertson, Executive Counsel | ||
| DeDe Sheel, Vice Relation | ||
| James Harrell, Head Relations |
Aurinia Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Aurinia Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0578 | ||||
| Return On Asset | -0.0216 | ||||
| Profit Margin | (0.10) % | ||||
| Operating Margin | 0.17 % | ||||
| Current Valuation | 1.01 B | ||||
| Shares Outstanding | 143.18 M | ||||
| Shares Owned By Insiders | 7.20 % | ||||
| Shares Owned By Institutions | 42.72 % | ||||
| Number Of Shares Shorted | 6.88 M | ||||
| Price To Earning | (4.83) X |
Currently Active Assets on Macroaxis
When determining whether Aurinia Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aurinia Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aurinia Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aurinia Pharmaceuticals Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aurinia Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Aurinia Stock please use our How to Invest in Aurinia Pharmaceuticals guide.You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aurinia Pharmaceuticals. If investors know Aurinia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aurinia Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.15) | Revenue Per Share 1.536 | Quarterly Revenue Growth 0.243 | Return On Assets (0.02) | Return On Equity (0.06) |
The market value of Aurinia Pharmaceuticals is measured differently than its book value, which is the value of Aurinia that is recorded on the company's balance sheet. Investors also form their own opinion of Aurinia Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Aurinia Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aurinia Pharmaceuticals' market value can be influenced by many factors that don't directly affect Aurinia Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aurinia Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aurinia Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aurinia Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.